Assessment of the antibody response in 110 healthy individuals who have been subject to Vi capsular polysaccharide vaccine

Dizer, Ufuk; Görenek, Levent; Güner, Özgür R; Pehlivan, Tamer; Özgüven, Volkan; Pahsa, Alaaddin

doi:10.1016/s0264-410x(02)00257-8

Cited by 9 publications

(5 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, subjects may have had a prevaccination anti-Vi IgG response of Ͻ1 g/ml that increased to Ͼ1 g/ml postvaccination, although the increase in antibody response may not have met the seroconversion criteria of increasing at least 4-fold after vaccination. Others have reported that 85 to 95% of subjects vaccinated with Vi polysaccharide develop protective levels of serum anti-Vi (18,42) or serum agglutinating antibody (9). Therefore, the pre-and postvaccination serum antibody titers observed in our study as measured with a bead immunoassay are in agreement with the vaccine-induced serum antibody responses measured by ELISA or tube agglutination assays.…”

Section: Discussionsupporting

confidence: 89%

Development of a Bead Immunoassay To Measure Vi Polysaccharide-Specific Serum IgG after Vaccination with the Salmonella enterica Serovar Typhi Vi Polysaccharide

Staats

Kirwan

Whisnant

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

Vi polysaccharide from Salmonella enterica serotype Typhi is used as one of the available vaccines to prevent typhoid fever. Measurement of Vi-specific serum antibodies after vaccination with Vi polysaccharide by enzyme-linked immunosorbent assay (ELISA) may be complicated due to poor binding of the Vi polysaccharide to ELISA plates resulting in poor reproducibility of measured antibody responses. We chemically conjugated Vi polysaccharide to fluorescent beads and performed studies to determine if a bead-based immunoassay provided a reproducible method to measure vaccine-induced anti-Vi serum IgG antibodies. Compared to ELISA, the Vi bead immunoassay had a lower background and therefore a greater signal-to-noise ratio. The Vi bead immunoassay was used to evaluate serum anti-Vi IgG in 996 subjects from the city of Kolkata, India, before and after vaccination. Due to the location being one where Salmonella serotype Typhi is endemic, approximately 45% of the subjects had protective levels of anti-Vi serum IgG (i.e., 1 g/ml anti-Vi IgG) before vaccination, and nearly 98% of the subjects had protective levels of anti-Vi serum IgG after vaccination. Our results demonstrate that a bead-based immunoassay provides an effective, reproducible method to measure serum anti-Vi IgG responses before and after vaccination with the Vi polysaccharide vaccine.

show abstract

Section: Discussionsupporting

confidence: 89%

Development of a Bead Immunoassay To Measure Vi Polysaccharide-Specific Serum IgG after Vaccination with the Salmonella enterica Serovar Typhi Vi Polysaccharide

Staats

Kirwan

Whisnant

et al. 2010

Clin Vaccine Immunol

View full text Add to dashboard Cite

show abstract

“…The Vi capsular polysaccharide vaccine is approved for children older than 2 years of age. A single parenteral dose provides a high level of protection 108,109 and may provide protection for as long as 10 years. The live attenuated vaccine, Ty21a, is similarly efficacious for a period of at least 5 years.…”

Section: S Typhimentioning

confidence: 99%

Acute, infectious diarrhea among children in developing countries

Podewils

Mintz

Nataro

et al. 2004

Seminars in Pediatric Infectious Diseases

115

View full text Add to dashboard Cite

show abstract

“…It might be expected that Vi antigen could confer a higher degree of protection in French, US, British and Philippinos but not in Nepalese and Indian population. In general, lower seroconversion rates were found in studies that included younger children like Acharya et al, 5 (5-15 years), Mirza et al, 7 (5-15 years), Rolande et al 8 (9-13 years) and higher seroconversion rates found in studies done in adults as by Arnold et al 9 and Diser et al 11 The method of estimation of anti-Vi anibodies and criteria used for seroconversion may also explain the variation in the seroconversion rates. In the study by Arnold et al 9 where seroconversion was found to be more than 90%, radioimmunoassay was used to assess the anti Vi antibodies.…”

Section: Discussionmentioning

confidence: 88%

“…Overall incidence of adverse effects was much lower than that seen in other studies. 7,9,11 Fever was the most common adverse reaction unlike pain in other studies. 7,9 The study highlights the low seroprevalence of Vi antibodies in children less than 5 years of age and that the Typhim Vi polysaccharide vaccine is safe and immunogenic between 2-5 years of age.…”

confidence: 83%

“…The seroprotection level was defined as an anti Vi antibody titre >1.5 mmol/l and seroconversion, as increase in the specific antibody to >0.15 mmol/l. Diser et al 11 estimated anti Vi antibodies by tube agglutination and dilution ratio of 1:40 or higher was regarded as protective antibody level. Kietel et al 12 found seroconversion rate of 92% at 1 month after vaccination.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Seroprevalence of anti Vi antibodies and immunogenicity of Typhim Vi vaccine in children

Gupta

Faridi²,

Aggarwal³

2008

Human Vaccines

View full text Add to dashboard Cite

This prospective study was carried out on 250 children between 6 months to 5 years of age to determine seroprevalence of anti Vi antibodies and to measure seroresponse and percent seroconversion to TyphimVi polysaccharide vaccine in children 2-5 years of age. Fifty children each were enrolled between 6 to 12 months of age (Group A), between 1- 2 years of age(Group B), between 2-3 years of age (Group C), between 3-4 years of age (Group D) and between 4-5 years of age (Group E). Anti-Vi antibody baseline titres were determined in all children. Children in Groups C to E were vaccinated with Typhim Vi vaccine. Baseline and postvaccination antibody titres were determined by ELISA. Test sera which had antibody levels >1 microg/ml were scored as seropositive. Of 250 children, 3 had base line anti-Vi antibodies >1 microg/ml. Following immunization overall seroconversion rate was 77.5% with 65.3%, 78.2% and 88% children showing seroconversion in Groups C, D and E respectively. Seroconversion was significantly more in Group E children compared to Group C (p=0.0148). There were no significant adverse reactions following vaccination. The study highlights very low prevalence of baseline anti Vi antibodies in children between 6 months and less than 5 years of age and shows high immunogenicity and safety of Typhim Vi polysaccharide vaccine in children 2-5 years of age.

show abstract

Assessment of the antibody response in 110 healthy individuals who have been subject to Vi capsular polysaccharide vaccine

Cited by 9 publications

References 5 publications

Development of a Bead Immunoassay To Measure Vi Polysaccharide-Specific Serum IgG after Vaccination with the Salmonella enterica Serovar Typhi Vi Polysaccharide

Development of a Bead Immunoassay To Measure Vi Polysaccharide-Specific Serum IgG after Vaccination with the Salmonella enterica Serovar Typhi Vi Polysaccharide

Acute, infectious diarrhea among children in developing countries

Seroprevalence of anti Vi antibodies and immunogenicity of Typhim Vi vaccine in children

Contact Info

Product

Resources

About